



## **Integra LifeSciences to Present At Upcoming Healthcare Conferences**

PLAINSBORO, N.J., Oct. 30, 2006 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Cowen and Company 7th Annual Global Health Care Conference in London and at the CIBC World Markets 17th Annual Healthcare Conference in New York City on Wednesday, November 8, 2006.

The Cowen presentation will be delivered by John B. Henneman, III, Executive Vice President and Chief Administrative Officer of Integra. A live webcast of this presentation can be accessed through a link provided in the Investor Relations section of Integra's website at <http://www.integra-ls.com>. Participants will be required to pre-register for the webcast at no charge. Additionally, a replay of the webcast will be available through Wednesday, November 22, 2006.

The CIBC presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. The CIBC presentation will not be available via webcast.

Each of the presentations will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels, and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.Integra-LS.com>.

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation  
John B. Henneman, III, Executive Vice President,  
Chief Administrative Officer  
(609) 936-2481  
[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)  
John Bostjancic, Vice President, Corporate Development and Investor Relations  
(609) 936-2239  
[jbostjancic@integra-LS.com](mailto:jbostjancic@integra-LS.com)